A global licensing agreement between Sunovion Pharmaceuticals and Japan’s Otsuka Pharmaceutical (TYO: 4578) will see the firms jointly develop and sell four compounds in neuropsychiatry.
Sunovion is a USA-based subsidiary of Sumitomo Dainippon Pharma (TYO: 4506).
The agreement covers ulotaront (SEP-363856), SEP-4199, SEP-378614 and SEP-380135, compounds which offer a scientifically unique approach to tackling conditions where there is unmet medical need.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze